Sanofi and Regeneron’s blockbuster biologic Dupixent (dupilumab) is poised for yet another label expansion, this time for the rare autoimmune skin disorder bullous pemphigoid (BP). The US Food ...
Feb 4 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and ...
Regeneron's gene therapy study shows improved hearing in children with congenital deafness Regeneron Pharmaceuticals said on Monday its experimental gene therapy showed improved hearing in 10 of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback